Particle arc therapy: Status and potential

Stewart Mein¹, Sophie Wuyckens², Xiaoqiang Li³, Stefan Both⁴, Alejandro Carabe⁵, Macarena Chocan Vera², Erik Engwall⁶, Fracchiolla Francesco⁷, Christian Graeff⁸, Wenbo Gu⁹, Liu Hong¹⁰, Taku Inaniwa¹¹, Guillaume Janssens¹⁰, Bas de Jong⁴, Taoran Li⁹, Xiaoying Liang¹², Gang Liu¹³, Antony Lomax¹⁴, Thomas Mackie¹⁵, Andrea Mairani¹⁶, Alejandro Mazal¹⁷, Konrad P Nesteruk¹⁸, Harald Paganetti¹⁸, Juan María Pérez Moreno¹⁷, Niek Schreuder¹⁹, Martin Soukup²⁰, Sodai Tanaka²¹, Thomas Tessonnier²², Lennart Volz⁸, Lewei Zhao²³, Xuanfeng Ding²⁴

Affiliations

¹ Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA; Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: s.mein@dkfz.de.
² UCLouvain, Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
³ Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA.
⁴ Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands.
⁵ Hampton University Proton Institute, Hampton, VA, USA.
⁶ RaySearch Laboratories AB, Stockholm, Sweden.
⁷ UO Fisica Sanitaria APSS, Trento, Italy.
⁸ GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany; Technische Universität Darmstadt, Institut für Physik Kondensierter Materie, Darmstadt, Germany.
⁹ Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰ Ion Beam Applications SA, Louvain-la-Neuve, Belgium.
¹¹ Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Medical Physics and Engineering, Graduate School of Medicine, Division of Health Sciences, Osaka University, Osaka, Japan.
¹² Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
¹³ Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
¹⁴ Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland; ETH, Department of Physics, Zürich, Switzerland.
¹⁵ Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI, USA.
¹⁶ Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; National Centre of Oncological Hadrontherapy (CNAO), Medical Physics, Pavia, Italy.
¹⁷ Centro de Protonterapia Quironsalud, Madrid, Spain.
¹⁸ Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA.
¹⁹ Leo Cancer Care, Knoxville, TN, USA.
²⁰ Elekta, Stockholm, Sweden.
²¹ Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
²² Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.
²³ Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
²⁴ Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA. Electronic address: xuanfeng.ding@corewellhealth.org.

PMID: 39009306
DOI: 10.1016/j.radonc.2024.110434

Free article

Review

Particle arc therapy: Status and potential

Stewart Mein et al. Radiother Oncol. 2024 Oct.

Free article

. 2024 Oct:199:110434.

doi: 10.1016/j.radonc.2024.110434. Epub 2024 Jul 14.

Authors

Affiliations

¹ Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA; Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: s.mein@dkfz.de.
² UCLouvain, Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium.
³ Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA.
⁴ Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands.
⁵ Hampton University Proton Institute, Hampton, VA, USA.
⁶ RaySearch Laboratories AB, Stockholm, Sweden.
⁷ UO Fisica Sanitaria APSS, Trento, Italy.
⁸ GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany; Technische Universität Darmstadt, Institut für Physik Kondensierter Materie, Darmstadt, Germany.
⁹ Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰ Ion Beam Applications SA, Louvain-la-Neuve, Belgium.
¹¹ Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Medical Physics and Engineering, Graduate School of Medicine, Division of Health Sciences, Osaka University, Osaka, Japan.
¹² Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
¹³ Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
¹⁴ Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland; ETH, Department of Physics, Zürich, Switzerland.
¹⁵ Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI, USA.
¹⁶ Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; National Centre of Oncological Hadrontherapy (CNAO), Medical Physics, Pavia, Italy.
¹⁷ Centro de Protonterapia Quironsalud, Madrid, Spain.
¹⁸ Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA.
¹⁹ Leo Cancer Care, Knoxville, TN, USA.
²⁰ Elekta, Stockholm, Sweden.
²¹ Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
²² Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.
²³ Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
²⁴ Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA. Electronic address: xuanfeng.ding@corewellhealth.org.

PMID: 39009306
DOI: 10.1016/j.radonc.2024.110434

Abstract

There is a rising interest in developing and utilizing arc delivery techniques with charged particle beams, e.g., proton, carbon or other ions, for clinical implementation. In this work, perspectives from the European Society for Radiotherapy and Oncology (ESTRO) 2022 physics workshop on particle arc therapy are reported. This outlook provides an outline and prospective vision for the path forward to clinically deliverable proton, carbon, and other ion arc treatments. Through the collaboration among industry, academic, and clinical research and development, the scientific landscape and outlook for particle arc therapy are presented here to help our community understand the physics, radiobiology, and clinical principles. The work is presented in three main sections: (i) treatment planning, (ii) treatment delivery, and (iii) clinical outlook.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sophie Wuyckens is funded by the Walloon Region as part of the Arc Proton Therapy convention (Pôles Mecatech et Biowin). Liu Hong and Guillaume Jansens are employed by ION BEAM APPLICATIONS SA (IBA Ltd). Research by Bas De Jong and Stefan Both is partly funded byION BEAM APPLICATIONS SA (IBA Ltd). Thomas Mackie is on the Board and has a financialinterest(stocks) and salary from Leo Cancer Care.Erik Engwall is employed by RaySearch. Martin Soukup is employed by Elekta. Xuanfeng Ding and Xiaoqiang Li have patents related to the particle arc therapy and it has been licensed to IBA. Xuanfeng Ding received honorium from IBA and Elekta’s speaker Bureau and the research project on proton arc therapy is in part supported by IBA and Elekta.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Particle arc therapy: Status and potential

Affiliations

Particle arc therapy: Status and potential

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical